OncoCyte Corporation announced the initiation of the company’s Analytical Validation study of DetermaVu Lung, its liquid biopsy test for lung cancer. Having recently achieved very positive results from its R&D Validation study, OncoCyte is now working to complete the remaining development studies required for commercialization of DetermaVu, including Analytical Validation, CLIA Validation and Clinical Validation. Assuming positive results from these studies, the company remains on-track to make its DetermaVu lung cancer assay commercially available in the second half of 2019.
https://thefly.com/landingPageNews.php?id=2873991
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.